Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population

International Journal of Gynecological Cancer

Volumn 19, Issue 8, 2009, Pages 1384-1389

  Gorelick, Constantine ^a   Andikyan, Vaagn ^a   MacK, Mendy ^a   Lee, Yi Chun ^a   Abulafia, Ovadia ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Endometrial cancer; Preoperative; Thrombocytosis

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTOSIS; TUMOR VOLUME; URBAN POPULATION; UTERUS TUMOR;

AFRICAN AMERICANS; AGED; CARIBBEAN REGION; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; POPULATION GROUPS; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; THROMBOCYTOSIS;

EID: 73349141699     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a47d47     Document Type: Article

References (47)

1. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004;30:95-108.
2. Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer. 1992;70:709-713.
3. Wu CW, Wang SR, Chao MF, et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol. 1996;91: 1417-1422.
4. Lidor YJ, Xu FJ, Martinez-Maza O, et al. Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res. 1993;207:332-339.
5. Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett. 1995;95:207-212.
6. Pinedo HM, Verheul HM, D'Amato RJ, et al. Involvement of platelets in tumour angiogenesis? Lancet. 1998;352:1775-1777.
7. Kisucka J, Butterfield CE, Duda DG, et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A. 2006;103:855-860.
8. Coller BS. Anti-GpIIb/IIIa drugs: current strategies and future directions. Thromb Haemost. 2001;86:427-443.
9. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost. 1995;74: 282-290.
10. Trikha M, Zhou Z, Timar J, et al. Multiple roles for platelet GPIIb/IIa and platelet alpha v beta 3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 2002;62:2824-2833.
11. Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cellYinduced platelet aggregation and lung metastasis by the oral GpIIb-IIIa antagonist XV454. Thromb Haemost. 2003;90:549-554.
12. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113: 723-731.
13. Costantini V, Zacharski LR, Moritz TE, et al. The platelet count in carcinoma of the lung and colon. Thromb Haemost. 1990;64:501-505.
14. Monreal M, Fernandez-Llamazares J, Pinol M, et al. Platelet count and survival in patients with colorectal cancer-a preliminary study. Thromb Haemost. 1998;79:916-918.
15. Li AJ, Madden AC, Cass I, et al. The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol. 2004; 92:211-214.
16. Zeimet AG, Marth C, Muller-Holzner E, et al. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1994;170:549-554.
17. Hernandez E, Lavine M, Dunton CJ, et al. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer. 1992;69: 2975-2977.
18. Hernandez E, Donohue KA, Anderson LL, et al. The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;78:137-142.
19. Hefler L, Mayerhofer K, Leibman B, et al. Tumor anemia and thrombocytosis in patients with vulvar cancer. Tumour Biol. 2000;21: 309-314.
20. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 1996;9:1826-1830. (Pubitemid 26294751)
21. Silvis SE, Turkbas N, Doscherholmen A. Thrombocytosis in patients with lung cancer. JAMA. 1970;211:1852-1853.
22. Shimada H, Oohira G, Okazumi S, et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004;198:737-741.
23. Taucher S, Salat A, Gnant M, et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost. 2003;89:1098-1106.
24. Symbas NP, Townsend MF, El-Galley R, et al. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000;86:203-207.
25. O'Keefe SC, Marshall FF, Issa MM, et al. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol. 2002;168:1378-1380.
26. Erdemir F, Kilciler M, Bedir S, et al. Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int. 2007;79:111-116.
27. Ikeda M, Furukawa H, Imamura H, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9:287-291.
28. Tamussino KF, Gücer F, Reich O, et al. Pretreatment hemoglobin, platelet count, and prognosis in endometrial carcinoma. Int J Gynecol Cancer. 2001;11:236-240.
29. Scholz HS, Petru E, Gücer F, et al. Preoperative thrombocytosis is anindependent prognostic factor in stage III and IV endometrial cancer. Anticancer Res. 2000;20:3983-3985.
30. Gücer F, Moser F, Tamussino K, et al. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol. 1998;70:210-214.
31. Pedersen LM, Milman N. Diagnostic significance of platelet count and other blood analyses in patients with lung cancer. Oncol Rep. 2003;10:213-216.
32. Burstein SA, Harker LA. Control of platelet production. Clin Haematol. 1983;12:3-22.
33. Metcalf D, Nicola NA, Gearing DP. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood. 1990;76:50-56.
34. Asano S, Okano A, Ozawa K, et al. In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets. Blood. 1990;75:1602-1605.
35. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992;52:3317-3322.
36. Tsukamoto T, Kumamoto Y, Miyao N, et al. Interleukin-6 in renal cell carcinoma. J Urol. 1992;148:1778-1781; [discussion 1781-1782].
37. Dosquet C, Schaetz A, Faucher C, et al. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer. 1994;30A:162-167.
38. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720-2725.
39. Chopra V, Dinh TV, Hannigan EV. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial carcinoma. J Cancer Res Clin Oncol. 1997;123:167-172.
40. Scambia G, Testa U, Panici PB, et al. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer. 1994;57: 318-323.
41. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med. 1981;95:636-641. (Pubitemid 12231807)
42. Smith MSH, Rothman V. Thrombospondin (TSP) levels in patients with malignancy. Proc Am Soc Clin Oncol. 1990:6.
43. Verheul HM, Pinedo HM. Tumor growth: a putative role for platelets? Oncologist. 1998;3:II.
44. Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007;13:7487-7495.
45. Dirix LY, Vermeulen PB, Hubens G, et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol. 1996;7:843-848.
46. Guo P, Hu B, Gu W, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol. 2003;162:1083-1093.
47. Vinals F, Pouyssegur J. Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGFalpha signaling. Mol Cell Biol. 2001;21:7218-7230